ReviewArchives of endocrinology and metabolism2022
Anabolic therapy for osteoporosis: update on efficacy and safety.
Review in Archives of endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 5 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- The Anabolic-First Strategy in Osteoporosis: A Systematic Review and Meta-Analysis of Fracture Outcomes in Patients at Very High Fracture Risk.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Adynamic bone disorder in chronic kidney disease: meta-analysis and narrative review of potential biomarkers as diagnosis and therapeutic targets.Renal failure · 2025Pooled it
- Romosozumab adverse event profile: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023.Aging clinical and experimental research · 2025Pooled it
- Effects of anti-osteoporotic drugs in patients with chronic kidney disease: a systemic review and network meta-analysis of bone mineral density, clinical fracture rate and renal function.Frontiers in pharmacology · 2025Pooled it
- Impact of anti-fracture medications on bone material and strength properties: a systematic review and meta-analysis.Frontiers in endocrinology · 2024Pooled it
- Osteoporosis in Pediatric Orthopaedics: Congenital Diseases, Medical Management, and Perioperative Considerations.Current osteoporosis reports · 2026Review
- Modern pharmacological management of Osteoporosis: from monotherapy to sequential and combination approaches in postmenopausal women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Review
- Bone-specific alkaline phosphatase as a marker of bone formation: Clinical and imaging correlates.World journal of experimental medicine · 2026Review
- Restoring skeletal remodeling in antiresorptive-treated patients: clinical outcomes of teriparatide in medication-related osteonecrosis of the jaw.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Review
- Inhibition of AXL receptor tyrosine kinase increases osteoblast function and bone mass.Bone research · 2026Article
- Activation of BMPR1b-SMAD pathway by Ginsenoside F1 restores osteoblast function in ovariectomy-induced osteoporosis.Journal of ginseng research · 2026Article
- Platelet-derived biomaterials in osteoporosis: mechanisms, evidence and translational prospects.Journal of biological engineering · 2026Review
- The Gut-Bone Axis: A Systematic Review on the Potential Intervention Pathways for Bone Health.Life (Basel, Switzerland) · 2026Review
- Sequential Versus Step-Therapy Approaches for Osteoporosis Management in Orthopedic Subspecialties.Current osteoporosis reports · 2026Review
- Anabolics in Cancer Patients: To Use or Not to Use?Endocrinology and metabolism (Seoul, Korea) · 2026Review
- Bone Organoids as Advanced Models for Osteoporosis: Development, Application, and Future Prospects.International journal of molecular sciences · 2026Review
- Implementation of a Modified Fracture Liaison Service at Aarhus University Hospital: A 2-Year Retrospective Cohort Study.Calcified tissue international · 2026Article
- Plants used in medicines and foods in osteoporosis: mechanistic insights into bone-remodeling homeostasis and clinical evidence.Frontiers in pharmacology · 2026Review
- Progress on novel compounds for the treatment of bone metabolism-related disorders: focus on osteoporosis and beyond.Frontiers in chemistry · 2026Review
- Longitudinal osteoporosis therapy: treat-to-target and sequential strategies-a narrative review.Therapeutic advances in musculoskeletal disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anabolic agents for the treatment of osteoporosis increase bone density, improve bone strength, and reduce fracture risk. They are distinguished from antiresorptive drugs by their property of increasing osteoblastic bone formation. Teriparatide and abaloparatide are parathyroid hormone receptor agonists that increase bone remodeling with bone formation increasing more than bone resorption. Romosozumab is a humanized monoclonal antibody to sclerostin that has a "dual effect" of increasing bone formation while decreasing bone resorption. The bone forming effects of anabolic therapy appear to be self-limited, making it imperative that it be followed by antiresorptive therapy to enhance or consolidate the beneficial effects achieved. Teriparatide, abaloparatide, and romosozumab each have unique pharmacological properties that must be appreciated when using them to treat patients at high risk for fracture. Clinical trials have shown a favorable balance of expected benefits and possible risks. Anabolic therapy is superior to bisphosphonates for high-risk patients, with greater benefit when initial treatment is with an anabolic agent followed by an antiresorptive drug, rather than the reverse sequence of therapy. Recent clinical practice guidelines have included recommendations with examples of patients who are candidates with anabolic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.